Key Proteo Achieves CLIA Certification: Launching Diagnostic Testing for Four Rare Diseases

Key Proteo is proud to announce that it has received a CLIA (Clinical Laboratory Improvement Amendments) certification, authorizing the laboratory to perform diagnostic testing on human specimens. This certification ensures that our laboratory meets federal regulatory standards for quality, accuracy, and reliability in diagnostic testing, which are essential for safeguarding patient health and supporting clinical decision-making.

Key Proteo will now be offering diagnostic testing for four rare diseases (Wilson Disease, Wiskott Aldrich Syndrome, X-linked Agammaglobulinemia, and adenosine deaminase (ADA) deficiency). Our diagnostic testing services will provide healthcare providers and patients with dependable and timely results that are critical for early diagnosis and effective care. Information on how to request our diagnostic services will be available shortly.

CLIA certification is a key milestone that affirms Key Proteo's commitment to excellence in laboratory practices and underscores the trust placed in our diagnostic services. We’re excited to bring these high-quality screening solutions to the healthcare community and to continue driving better outcomes for patients and families.